21 – 30 of 112
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Pneumococcal vaccine in adults with immune-mediated inflammatory diseases
- Contribution to journal › Debate/Note/Editorial
-
Mark
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate : Are They Interchangeable?
- Contribution to journal › Article
-
Mark
Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
- Contribution to journal › Article
-
Mark
Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis : what is the role of inflammation control?
- Contribution to journal › Article
-
Mark
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries
- Contribution to journal › Article
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
- Contribution to journal › Article
-
Mark
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
- Contribution to journal › Article
-
Mark
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
- Contribution to journal › Article
-
Mark
Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Contribution to journal › Article
